StocksMarket.in

Tag "Q1FY22"

 Breaking News

Corporate insolvency filings reduce in Q1FY22, after lifting of moratorium

According to the latest data from the Insolvency and Bankruptcy Board of India (IBBI), 126 cases were admitted between April and June 2021. (Representative Image) In the first quarter of

Read Full Article

Q1FY22 review: Top 10 plays on digitization and demand recovery

Out of 700 companies’ quarterly results, the median revenue growth is 47 percent on a YoY basis. The net margins of the companies have been reported as median of 8.2

Read Full Article

Cipla posts 24% YoY net profit growth in Q1FY22 led by core therapies, COVID portfolio

India business that includes branded formulations, trade generics and consumer health grew by 68% YoY to Rs 2,710 crore driven by volume growth in core therapies and support from existing

Read Full Article

Exide Industries reports Rs 31.8 crore profit in Q1FY22

Exide Industries had posted a loss of Rs 13.5 crore in the same period of the last financial year, it said in a regulatory filing. PTI July 31, 2021 /

Read Full Article

Sun Pharma share price locked in 10% upper circuit on turning profitable in Q1FY22

Sun Pharma has reported a net profit of Rs 1,444.1 crore in the quarter ended Q1FY22 against a loss of Rs 1,655.6 crore in the year-ago period ‘); $ (‘#lastUpdated_’+articleId).text(resData[stkKey][‘lastupdate’]);

Read Full Article

Jubilant Pharmova profit jumps 350% to Rs 160 crore in Q1FY22

The net profit jump was led by gradual recovery in specialty radiopharmaceutical business hit by COVID-19, traction in contract manufacturing and generics segment performing well on COVID antiviral drug Remdesivir

Read Full Article

Gland Pharma Q1FY22 profit rises 12% on new launches, COVID drugs Remdesivir and Enoxaparin

Revenue from operations rose 31 percent YoY to Rs 1,153.9 crore in Q1FY22 versus Rs 884.2 crore in Q1FY21. Gland

Read Full Article

DAILY VOICE | Nifty target upgraded to 17,400 for December 2021, Q1FY22 earnings commentary critical, says Neeraj Chadawar of Axis Securities

Neeraj Chadawar, Head, Quantitative Equity Research, Axis Securities, expects a 31 percent earnings growth in FY22. Normal monsoon and a

Read Full Article

Alkem Labs sees huge sales momentum of anti-infectives in Q1FY22

Secondary infections due to bacteria and fungus have gained traction pushing up sales; healthy momentum in chronic therapies and increased

Read Full Article

Interview | We could possibly see earnings downgrades after Q1FY22 results: Rusmik Oza of Kotak Securities

Rusmik Oza, Executive Vice President, Head of Fundamental Research at Kotak Securities feels going by the second wave pattern of

Read Full Article

Archives